(Q40670096)

22 September 2017

title

alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs (English)

1 reference

22 September 2017

Hans O Kalkman

1

1 reference

22 September 2017

Erika Loetscher

series ordinal

2

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

European Journal of Pharmacology

22 September 2017

published in

1 reference

22 September 2017

volume

462

1 reference

22 September 2017

issue

1-3

1 reference

22 September 2017

page(s)

33-40

1 reference

The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

High-efficiency transformation of mammalian cells by plasmid DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Mechanism of peripheral noradrenergic stimulation by clozapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

The effect of clozapine on the speed and accuracy of information processing in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Facilitation of cognitive functions by a specific alpha2-adrenoceptor antagonist, atipamezole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Guanfacine, but not clonidine, improves planning and working memory performance in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Psychomotor impairment and cognitive disturbances induced by neuroleptics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

The alpha 2 adrenoceptor antagonists RX 821002 and yohimbine delay-dependently impair choice accuracy in a delayed non-matching-to-position task in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Comparative effects of clozapine and α-adrenoceptor blocking drugs on regional noradrenaline metabolism in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Idazoxan potentiates rather than antagonizes some of the cognitive effects of clonidine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Neuropsychological change in schizophrenia after 6 weeks of clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Attenuation of delay-period activity of monkey prefrontal neurons by an alpha2-adrenergic antagonist during an oculomotor delayed-response task

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Antipsychotic drug doses and neuroleptic/dopamine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Novel dopamine receptors half a decade later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Modulation of neurotransmitter release by presynaptic autoreceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

Muscarinic m4 receptor activation by some atypical antipsychotic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2803%2901308-6

10.1016/S0014-2999(03)01308-6

7 January 2021

Identifiers

DOI

1 reference

22 September 2017

1 reference